Vedolizumab for induction and maintenance of remission in Crohn's disease

BACKGROUND: Vedolizumab blocks inflammatory activity within the gastrointestinal tract. Systematic reviews have demonstrated the efficacy of vedolizumab in ulcerative colitis and inflammatory bowel disease in general. This systematic review and meta‐analysis summarises the current evidence of vedoli...

Descripción completa

Detalles Bibliográficos
Autores principales: Hui, Samuel, Sinopoulou, Vassiliki, Gordon, Morris, Aali, Ghazaleh, Krishna, Anuj, Ding, Nik Sheng, Boyapati, Ray K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351211/
https://www.ncbi.nlm.nih.gov/pubmed/37458279
http://dx.doi.org/10.1002/14651858.CD013611.pub2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351211/
https://www.ncbi.nlm.nih.gov/pubmed/37458279
http://dx.doi.org/10.1002/14651858.CD013611.pub2

Ejemplares similares